U.S. Stem Cell, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From U.S. Stem Cell, Inc.
Urology device developer NeoTract, which Teleflex purchased in 2017, is now under scrutiny for potential FCA violations.
Story and Podcast: Teleflex Medical launched in March a novel portfolio of miniaturized percutaneous surgical instruments that have the same functionality as full-sized laparoscopic instruments, but allow surgeons to access the abdominal cavity using trocar-less entry and much smaller incisions than those required in traditional laparoscopy. Teleflex execs say the technology is a game changer, and the company hopes percutaneous laparoscopy will become the standard of care for the 4 million laparoscopic procedures performed annually in the US.
Twelve FDA close-out letters were released in September.
The company recalled its Hudson RCI Lifesaver resuscitation devices after it was found they were defective and could lead to injury or death if their oxygen intake ports get blocked.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Bioheart Inc.